Department of Oncology, Zhujiang Hospital, Southern Medical University, 253 Industrial Avenue, Guangzhou, Guangdong, 510282, People's Republic of China.
The First School of Clinical Medicine, Southern Medical University, 1838 Guangzhou Avenue North, Guangzhou, Guangdong, 510515, People's Republic of China.
J Exp Clin Cancer Res. 2022 Sep 7;41(1):268. doi: 10.1186/s13046-022-02469-0.
As our understanding of the mechanisms of cancer treatment has increased, a growing number of studies demonstrate pathways through which DNA damage repair (DDR) affects the immune system. At the same time, the varied response of patients to immune checkpoint blockade (ICB) therapy has prompted the discovery of various predictive biomarkers and the study of combination therapy. Here, our investigation explores the interactions involved in combination therapy, accompanied by a review that summarizes currently identified and promising predictors of response to immune checkpoint inhibitors (ICIs) that are useful for classifying oncology patients. In addition, this work, which discusses immunogenicity and several components of the tumor immune microenvironment, serves to illustrate the mechanism by which higher response rates and improved efficacy of DDR inhibitors (DDRi) in combination with ICIs are achieved.
随着我们对癌症治疗机制的理解不断加深，越来越多的研究表明 DNA 损伤修复 (DDR) 途径如何影响免疫系统。与此同时，患者对免疫检查点阻断 (ICB) 治疗的反应各不相同，这促使人们发现了各种预测性生物标志物，并研究了联合治疗。在这里，我们的研究探讨了联合治疗中涉及的相互作用，并对目前已确定的和有前途的免疫检查点抑制剂 (ICI) 反应预测因子进行了综述，这些预测因子有助于对肿瘤患者进行分类。此外，这项讨论免疫原性和肿瘤免疫微环境几个组成部分的工作，说明了 DDR 抑制剂 (DDRi) 与 ICI 联合使用时为何能提高反应率和疗效。
